tbuckley/cabot-search huggingface dataset:
Controlled-Dose Chemotherapy as an Adjunct to Surgery
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bookends Pro
Authors: John R. Tkach
Journal: JAMA (1997)

Bibliography You are writing an article for publication and want to prepare a bibliography from a MEDLINE search that retrieved 250 citations (or 1000), which you downloaded. Must you type them into the word processor by hand? Now there is a program that will let you import the downloaded database, search it, cite references, make a numbered bibliography corresponding to the text of your article, and export the bibliography into your word processor. Bookends is a powerful, helpful application that is fun to watch in action. (Caution: the ethical author does not cite articles from a bibliography without having obtained and read them in full.) Bookends is a database manager for authors. There may be citations that are not in the MEDLINE search such as books or other source citations. With Bookends, you can enter these additional references, even including personal communications. Bookends will allow you to format your citations
Introduction to the Study of Medicine.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LIMITATIONS OF GOITER PROPHYLAXIS
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
Authors: None Parkinson Study Group
Journal: JAMA (2002)

ContextPramipexole and levodopa are effective medications to treat motor symptoms of early Parkinson disease (PD). In vitro and animal studies suggest that pramipexole may protect and that levodopa may either protect or damage dopamine neurons. Neuroimaging offers the potential of an objective biomarker of dopamine neuron degeneration in PD patients.ObjectiveTo compare rates of dopamine neuron degeneration after initial treatment with pramipexole or levodopa in early PD by means of dopamine transporter imaging using single-photon emission computed tomography (SPECT) with 2β-carboxymethoxy-3β(4-iodophenyl)tropane (β-CIT) labeled with iodine 123.DesignSubstudy of a parallel-group, double-blind randomized clinical trial.Setting and PatientsEighty-two patients with early PD who were recruited at 17 clinical sites in the United States and Canada and required dopaminergic therapy to treat emerging disability, enrolled between November 1996 and August 1997.InterventionsPatients were randomly assigned to receive pramipexole, 0.5 mg 3 times per day with levodopa placebo (n = 42), or carbidopa/levodopa, 25/100 mg 3 times per day with pramipexole placebo (n = 40). For patients with residual disability, the dosage was escalated during the first 10 weeks, and subsequently, open-label levodopa could be added. After 24 months of follow-up, the dosage of study drug could be further modified.Main Outcome MeasuresThe primary outcome variable was the percentage change from baseline in striatal [123I]β-CIT uptake after 46 months. The percentage changes and absolute changes in striatal, putamen, and caudate [123I]β-CIT uptake after 22 and 34 months were also assessed. Clinical severity of PD was assessed using the Unified Parkinson Disease Rating Scale (UPDRS) 12 hours off anti-PD medications.ResultsSequential SPECT imaging showed a decline in mean (SD) [123I]β-CIT striatal uptake from baseline of 10.3% (9.8%) at 22 months, 15.3% (12.8%) at 34 months, and 20.7% (14.4%) at 46 months—approximately 5.2% per year. The mean (SD) percentage loss in striatal [123I]β-CIT uptake from baseline was significantly reduced in the pramipexole group compared with the levodopa group: 7.1% (9.0%) vs 13.5% (9.6%) at 22 months (P = .004); 10.9% (11.8%) vs 19.6% (12.4%) at 34 months (P = .009); and 16.0% (13.3%) vs 25.5% (14.1%) at 46 months (P = .01). The percentage loss from baseline in striatal [123I]β-CIT uptake was correlated with the change from baseline in UPDRS at the 46-month evaluation (r = − 0.40; P = .001).ConclusionsPatients initially treated with pramipexole demonstrated a reduction in loss of striatal [123I]β-CIT uptake, a marker of dopamine neuron degeneration, compared with those initially treated with levodopa, during a 46-month period. These imaging data highlight the need to further compare imaging and clinical end points of PD progression in long-term studies.
Fibrinolysis
Authors: Liberto Pechet
Journal: New England Journal of Medicine (1965)

MUCH scientific effort is being devoted to the study of the etiology and prevention of thromboembolic disease, one of the major "killers" in the United States. One approach that promises to have an important role makes use of a natural defense system possessed by the body, the fibrinolytic mechanism. Because of its pathogenetic implications and the therapeutic possibilities progress in fibrinolysis has a profound influence in the medical community.Since comprehensive reviews on fibrinolysis were published in 19581 and in 19612 this report will primarily consider the advances that have taken place within the past five years. A scheme of . . .
BRCA1 Tumor Suppression Requires the BRCT Domain
Journal: Cancer Discovery (2011)

Abstract Major finding: E3 ligase-defective BRCA1 suppresses cancer to the same degree as wild-type BRCA1. Strategy: Use of Brca1-mutant mouse models identified determinants of BRCA1 tumor suppression. Impact: The BRCT repeats may be critical for tumor suppression and therapeutic intervention.
Abstract 19562: PKG-I[[Unable to Display Character: &amp;#593;]] Oxidative Activation Regulates Small Artery Myogenic Tone Through Calcium Sparks and the BK Channel
Authors: Kaivan Khavandi, Rachael Baylie, Majid Ahmed, Sarah Sugden, Philip Eaton, Mark T Nelson, Adam Greenstein
Journal: Circulation (2015)

Small resistance arteries function in a state of partial constriction generated by vascular smooth muscle cells (VSMC) in response to intraluminal pressure (‘myogenic constriction’). Collectively, the degree of myogenic constriction determines peripheral resistance and so influences systemic blood pressure. cGMP-dependent protein kinase (PKG) is widely implicated in vascular physiology, but until now has been assumed to play no role in modulation of this important vascular function on the basis that inhibitors of cGMP have no influence on pressure-induced tone. Recent identification of a novel redox mechanism by which PKG can be activated independently of the ‘classical’ NO-sGC-cGMP pathway made it important to revisit PKG’s role in these processes. To examine the relative contribution of these pathways, a transgenic mouse model was utilized, in which a single point mutation precludes activation via oxidative dimerization of PKG, whist preserving classical activation by cGMP. Diameter studies of small arteries from this ‘knock-in’ model were investigated in a pressure-myograph system, and demonstrated reduced constitutively functioning BKCa channel activity in these animals, and in consequence markedly enhanced myogenic constriction. Through imaging of calcium sparks with a spinning disc confocal microscope, the loss of BKCa channel function was shown to be due to diminished VSMC calcium sparks. Patch clamp electrophysiological studies showed that the amplitude and frequency of spontaneous transient outward currents were also reduced, consistent with these findings. Pharmacological studies using both pressure and wire myography with the application of the oxidant hydrogen peroxide provided a signal that myogenic tone initiates oxidant-induced activation of PKG. Western blot analysis of vessels fixed during relevant functional responses confirmed that generation of pressure-induced tone triggers oxidant activation of PKG. Finally, optical monitoring confirmed elevated ROS production with the induction of tone. Our results provide a conceptual framework by which vascular tone is modulated through release of ROS and oxidant-activation of PKG through calcium signalling. This may have important implications for blood pressure.
PBI-4050 restores liver and adipose tissue metabolic homeostasis, and decreases fibrosis in a high-fat-diet mouse model of non-alcoholic fatty liver disease
Authors: Brigitte Grouix, Jean-Christophe Simard, Jean-Francois Thibodeau, Mikaël Tremblay, Alexandre Laverdure, François Sarra-Bournet, Ramon Corpuz, Lyne Gagnon
Journal: Journal of Hepatology (2020)
Pro-UK: another entry in the thrombolytic arena
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of safety, tolerability, and activity: A registry for temsirolimus-treated patients with advanced or metastatic renal cell carcinoma (aRCC) in the usual health care setting.
Authors: H. Pelz, G. Krekeler, L. Bergmann, J. Roigas, T. Steiner, P. Löschmann, M. Kosch
Journal: Journal of Clinical Oncology (2010)

e15127 Background: Temsirolimus (TEMS), an i.v. mTOR inhibitor, was approved in the EU for the first-line treatment of patients with aRCC who have at least 3 of 6 prognostic risk factors in Nov 2007. A pivotal study had demonstrated significantly increased overall survival with TEMS in poor risk aRCC compared to the former standard Interferon (10.9 mo vs 7.3 mo). To better identify the safety profile and efficacy of TEMS during clinical routine, collection of data on pharmacovigilance in the post-approval period is essential. Hence a non-interventional trial appears to be adequate. Methods: To prospectively evaluate TEMS in the usual health care setting a registry for TEMS-treated patients with aRCC was started in Germany in Jan 2008 (NCT00700258). Primary objective is the evaluation of TEMS's safety profile. Secondary objectives include the tolerability and activity of TEMS as well as the profile, comorbidity and characteristics of patients and sequence of systemic therapies in aRCC. Inclusion criteria are a histologically confirmed aRCC treated with TEMS and written informed consent by the patient. Results: 84 active centers recruited 278 pts from February 2008 to November 2009. Preliminary data are available on 220 pts (70% male, 30% female): median age 67.9 yrs (40.4 – 87.0), median Karnofsky index 80% (40 - 100%), clear cell carcinomas predominant (76.8%). 143 pts experienced 622 AEs, including 63 pts with 147 SAEs (47 of them considered related by the treating physician). Median PFS is 141 days. The subgroup of pts ≥ 65 yrs is equivalent to total study population regarding to number of AEs, SAEs, and median PFS. Conclusions: Patient population in the registry represents the expected pattern in aRCC regarding distribution of age, sex and histology. Safety profile and efficacy of TEMS are comparable to phase-III data. For patients ≥ 65 yrs safety and efficacy are similar to those of the overall study population. In August 2009 additional EU-approval for patients with recurrent and/or refractory MCL was granted for TEMS. Hence, by protocol amendment the registry is now open for MCL as well. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Wyeth Wyeth Wyeth Wyeth
Abstract 1246: Comprehensive RNA interference induced by CRISPR/Cas13a gene editing system in human cancer cells
Authors: Qixue Wang, Yunfei Wang, Yanli Tan, Chunsheng Kang
Journal: Cancer Research (2019)

Abstract RNA is the intermediate link of central dogma. However, RNA is rarely used as a therapeutic target for its flexible structure and instability. CRISPR/Cas13a is reported as a powerful tool for RNA knockdown. The potential amplification of CRISPR/Cas13a in cancer cells could be further studied. Here we overexpressed the Cas13a protein by lenti-virus vectors in glioma and other cancer cells, and found out that crRNA-EGFP could induce the “collateral effect” after knocking down the target gene. EGFRvIII is a unique EGFR mutant subtype in glioma. CRISPR/Cas13a system could induce cell death of EGFRvIII overexpression glioma cells. Single cell and RNA-seq analysis confirmed the comprehensive RNA interference by CRISPR/Cas13a treatment. Furthermore, CRISPR/Cas13a system could inhibit the formation of glioma intracranial tumor in mice. Our results exhibit the comprehensive RNA interference of CRISPR/Cas13a system in cancer cells, and demonstrated the powerful tumor elimination potential of this system. Citation Format: Qixue Wang, Yunfei Wang, Yanli Tan, Chunsheng Kang. Comprehensive RNA interference induced by CRISPR/Cas13a gene editing system in human cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1246.
Career Focus
Journal: BMJ (2004)

Notwithstanding some pessimistic views about the effects of biofeedback interventions for gastrointestinal conditions, w6 biofeedback training seems to be a good treatment for lower gastrointestinal disturbances, especially for pelvic floor dyssynergia.The effects of such training may not be limited to the anorectum and might also be useful in other conditions in which pelvic floor dyssynergia plays a role.w7 However, good quality research in this subject is lacking.Validated scoring systems and quantitative tests are still needed, as well as more uniform and strict criteria for pelvic floor dyssynergia. 1For good quality studies, we also need improved experimental designs, larger numbers of participants, clearly defined outcome measures, knowledge of the best treatment protocol, and long term follow up. 12Finally, it remains to be established whether other promising treatments for pelvic floor dyssynergia, whether used alone 25 or in combination with biofeedback, w8 could provide better clinical outcomes.
Hemicraniectomy Improves Outcomes for Patients With Ruptured Brain Aneurysms
Authors: M. Mitka
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COMBINATIONS OF MEDICAL MEN.
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply from the authors
Authors: Alvan R. Feinstein, Gary C. Curhan, Elizabeth Delzell, Paul J. DeSchepper, Johannes M. Fox, Helmut Graf, Lothar A.J. Heinemann, Friedrich C. Luft, Paul Michielsen, Michael J. Mihatsch, Samy Suissa, Fokko van der Woude, Stefan Willich
Journal: Kidney International (2001)
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
Authors: Dana Meaney-Delman, R Sascha, T Tom
Journal: New England Journal of Medicine (2021)

The authors reply: Sun appropriately raises questions about the proportion of women reporting spontaneous abortion in our recent article.We agree that the denominator used in that proportion -827 completed pregnancies -is not an appropriate denominator for the calculation of a risk estimate or rate.The number of spontaneous abortions (104) reflects data reported by the participants as of March 30, 2021, during telephone follow-up.In this preliminary report, follow-up information was missing for the majority of pregnancies in which exposure to vaccination occurred in early pregnancy.Among the 1224 women who had been vaccinated before conception or in the first trimester, follow-up through 20 weeks of gestation had been completed for only 204 pregnancies that were known to be ongoing and for 1 pregnancy that resulted in stillbirth.Among the pregnancies that had not yet reached 20 weeks of gestation, there were 10 pregnancies with other outcomes before 20 weeks of gestation, including 8 ectopic pregnancies and 2 induced abortions.For the other 905 pregnancies, followup had not occurred to establish whether these pregnancies were ongoing past 20 weeks of gestation.We have amended Table 4 in our earlier publication and have clarified the text.Subsequently, we completed telephone followup for the 905 pregnancies and enrolled additional persons in the v-safe pregnancy registry.To determine the cumulative risk of spontaneous abortion from 6 to less than 20 weeks of gestation, we used life-table methods to perform an updated analysis, now reported in the Journal, involving 2456 women who received at least one dose of an mRNA Covid-19 vaccine before conception or before 20 weeks of gestation. 1The estimated risks (14.1% overall and 12.8% in age-standardized analyses) are consistent with the risks of spontaneous abortion reported in the general population. 1